The North American life sciences landscape is undergoing a transformative shift, and one of the most compelling areas of this evolution is the cell-free protein synthesis reagents market. Valued at USD 157.49 million in 2024 and projected to reach USD 292.22 million by 2032, this segment is on a robust 7.5% CAGR trajectory, driven by innovations in biomanufacturing, synthetic biology, and...